48 results about "Elevated blood glucose" patented technology

FBPase inhibitors of the formula I and Xare useful in the treatment of diabetes and other conditions associated with elevated blood glucose or excess glycogen storage.

Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: and their use in the treatment of diabetes and other conditions associated with elevated blood glucose.

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.

Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.

Novel FBPase inhibitors of the formula I and X are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.

The invention discloses a sublingual cigarette and a preparation method of the sublingual cigarette and belongs to the field of novel tobacco products. The sublingual cigarette comprises, by mass, 0.01%-6% of nicotine, 3%-15% of non-carbonhydrate sweet substances, 5%-35% of sodium alginate, 45%-80% of green bean starch, 3%-8% of calcium sulphate, 0.5%-3% of licorzince, 0.2%-0.8% of vitamin and 0%-0.6 of menthol (or peppermint oil). Compared with existing novel tobacco products, the sublingual cigarette has the advantages that rapid sublingual dissolution can be achieved, onset is fast and no residue exists; the sweetness of the sweet substances is high, the dosage is small, and the cost is saved; the physiological needs of a consumer can be met, and the functions of decayed tooth prevention and oral ulcer can be achieved; elevated blood glucose can not be caused, and the sublingual cigarette is applicable to long-term use of the diabetic population.

The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

The present invention relates to methods for treating or delaying the onset of pathologies associated with elevated blood glucose and / or elevated blood pressure. The methods are directed to modulating, regulating, or inhibiting the expression or activity of Connective Tissue Growth Factor (CTGF) or fragments thereof.

A therapeutic or an edible composition comprising at least three of the five herbs selected from Prunus amygdales, Ocimum sanctum, Azadirachta indica, Aegle marelose and Vitus vinefera, is provided for the treatment of hyperglycemia, especially for non-insulin dependent diabetic subjects, and the herbal composition has significantly reduced the blood glucose levels in both diabetic and non-diabetic experimental subjects having elevated blood glucose levels.

The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver.

The present invention provides bitter gourd and Chinese caterpillar fungus and ganoderma lucidum powder. Dried bitter gourd sheets, Chinese caterpillar fungus powder, ganoderma lucidum powder and propolis are crushed and uniformly mixed to prepare the bitter gourd and Chinese caterpillar fungus and ganoderma lucidum powder, which is an edible health product for high blood glucose patients. The bitter gourd has effects of heat clearing, detoxification and significant blood glucose level decreasing. The Chinese caterpillar fungus provides a significant blood glucose level decreasing effect for blood glucose level increasing induced by ciclosporin A, and provides a certain inhibition effect for insulin secretion decreasing induced by the ciclosporin A. With the ganoderma lucidum, utilization of the glucose of the organization can be improved. After taking the ganoderma lucidum, the ganoderma lucidum can replace the insulin and inhibit the fatty acid releasing, such that the high blood glucose, urine glucose and other symptoms can be changed. With the propolis, the blood glucose level is regulated, the therapeutic effect of the hypoglycemic agent is improved, the symptoms of diabetes mellitus are improved, and complications of diabetes mellitus patients are prevented and controlled. The powder provided by the present invention has the following advantages: the formula is reasonable; the amount of the raw materials is proper; after the diabetes mellitus patient takes the powder, the effects of blood glucose level decreasing and blood glucose level stabilizing are provided; compared to the tablet and the capsule, the powder is the powder food, and is easy to be absorbed by the human body, such that the better and faster positive effects can be provided for the human body; no side effect is generated; a plurality of the complications induced by taking the western medicine can be avoided.

The invention provides compositions comprising Eno1 and a muscle targeting peptide, e.g, as a fusion protein, for delivery of Eno1 to a muscle. The Eno1 may contain one or more added cysteine residues which are covalently attached to a biocompatible polymer (e.g. polyethylene glycol). Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject.

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

The invention discloses nutritional breakfast for repairing the glucose tolerance factor. Buckwheat, shiitake and purple yams are mixed and decocted with water to form porridge, and then the nutritional breakfast is prepared; the weight ratio of the buckwheat to the shiitake to the purple yams to the water is 1:1:1:(3-4). Best food varieties are selected for preparing the nutritional breakfast, nutrition necessary to the glucose tolerance factor of the human body is provided, the nutrition of the glucose tolerance factor is balanced again, best nutrition is realized, nutrition damage of the glucose tolerance factor of type 2 diabetic patients and pre-diabetic patients with impaired fasting glucose and the damaged glucose tolerance factor can be repaired, the biological effect of insulin is better enhanced, utilization of in-vivo glucose is accelerated by activating phosphoglucomutase, the glucose is converted into fat, and elevated blood glucose is promoted to return to normal quickly. Thus, the dose of a medicine is reduced, complications of the diabetic patients are improved, the living quality is improved, and the life is prolonged.

The present invention discloses a method to reduce elevated blood glucose levels in a subject, typically having (pre-)diabetes, steatohepatitis, obesity, and / or metabolic syndrome, when orally administered. Particularly preferred compositions include a set of active components consisting of two or more isolated and purified saccharides selected from galacturonic acid, glucuronic acid, galactose, arabinose, glucuronic acid, rhamnose, xylose, and mannose. The composition administered to a subject in need thereof an effective dose of the composition for a period of at least 6 weeks, wherein administration results in an at least 5% reduction of blood glucose.

Novel FBPase inhibitors of the formula I are useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.

A method for a treatment selected from the group consisting of (a) reducing elevated blood glucose, (b) reducing complications of diseases that are associated with elevations of blood glucose, (c) prevention of diseases that develop as a result of elevated blood glucose, (d) controlling glucose metabolism in a mammal by means of an N-acylated hexosamine which is not effectively metabolized to glucose or glucosamine, (e) preventing the development of the metabolic syndrome, and (f) ameliorating the metabolic syndrome in a mammal that has developed the syndrome as a result of an other condition or conditions, such as ovarian failure or the post-menopausal state, in a mammal, the method comprising administering to the mammal an effective amount of a N-acylated-2-glucosamine derivative of the general formula (I): wherein R is an alkyl radical of the general formula CnH2n+1 wherein n is selected from 2-12; and pharmaceutically-acceptable salts, esters and glucosides thereof.

The invention relates to compositions comprising Pinus pinaster stem bark extract, papain, and Aloe vera extract, and methods of manufacturing same. There are also described methods of treating or preventing a variety of conditions, including treating or preventing elevated blood glucose, pre-diabetes, type 2 diabetes, autoimmune diseases, reducing or decreasing inflammation, treating or preventing diseases characterised by elevated levels of inflammation, and lowering blood cholesterol, said methods comprising administering an effective amount of a composition according to the invention to a subject in need thereof. Uses of the composition of the invention for the manufacture of a medicament for treating or preventing a variety of conditions are also described.

The present invention is directed to a method for treating individuals having inflammation or preventing inflammation in individuals at risk for inflammation, more specifically individuals with chronic inflammation as evidenced by elevated C-reactive protein, serum fibrinogen, elevated platelet count and platelet activity, elevated blood glucose, any component or combination of components of the metabolic syndrome by using the selected immunoregulators. The present invention also includes a method for preventing the development of inflammation in individuals at risk for inflammation by using the selected immunoregulators, and for deferring progression of the inflammatory state to the more specific outcomes of the Metabolic Syndrome including diabetes mellitus, coronary heart disease, and cancer.

Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses to act as a transport vehicle to deliver to target cells in the body, messenger RNA molecules. Delivering to the beta cells in the body the messenger RNA molecules needed to construct insulin or insulin receptors will lead to enhanced production of biologically active insulin or insulin receptors by beta cells as necessary, which will lead to correcting deficiencies in insulin or insulin receptors the result of which will help properly regulate blood glucose levels throughout the body utilizing innate regulatory mechanisms.

The invention provides the use of traditional Chinese medicinal rheum officinale and its extract in preparing medicament for reducing blood sugar. The original rheum officinale medicament, the water or organic solvent extract of rheum officinale can suppress the activity of alpha-glucosaccharase.

The present invention relates to methods of identifying whether one or more candidate compounds is a modulator of a G protein-coupled receptor (GPCR) or a modulator of blood glucose concentration. In certain embodiments, the GPCR is human. The present invention also relates to methods of using a modulator of the GPCR. A preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for lowering blood glucose concentration, for preventing or treating certain metabolic disorders, such as insulin resistance, impaired glucose tolerance, and diabetes, and for preventing or treating a complication of an elevated blood glucose concentration, such as atherosclerosis, heart disease, stroke, hypertension and peripheral vascular disease.

The invention discloses sugar-controlling cereal health-care powder, namely cereal health-care powder for inhibiting absorption of cane sugar and glucose. The health-care powder comprises, by weight, 1-25% of sesame powder, 1-25% of soybean meal, 1-25% of wheat flour, 1-25% of corn flour, 1-25% of walnut powder, 1-50% of oatmeal, 1-30% of cane sugar, 1-30% of tagatose and 1-30% of L-arabinose. The preparation steps comprise: Step 1, mixing: adding the raw materials which have been blended according to the standard mass ratio into a container and mixing; Step 2, sterilization: sterilizing by a microwave sterilization method; Step 3, testing: carrying out quality test on a finished product obtained after the sterilization; Step 4, tinning: tinning after qualified through the quality test; and Step 5, sealing: sealing the product obtained after tinning. On the basis of traditional cereal health-care powder, L-arabinose and tagatose are added to prevent human body from absorbing cane sugar and glucose so as to inhibit postprandial blood sugar from rising and reduce fat intake.

The invention relates to a preparation method of a preparation for treating diabetes. Diabetes is a chronic disease caused by a long-term effect of genetic factors and environmental factors. The main pathological basis of diabetes is absolute or relative insufficiency of insulin secretion in vivo and rise of blood glucose caused by reduction of cells on insulin sensitivity, and urine sugar appears to lead to fat, protein, mineral substance, water and acid-base unbalance in severity. Diabetes is an endocrine metabolic disease. The history of treating diabetes by traditional Chinese medicines is over thousand years, and the traditional Chinese medicines have outstanding contribution to treatment of diabetes. According to the preparation method provided by the invention, the effective substances for treating diabetes in traditional Chinese medicinal materials are prepared by applying a biotechnology at low temperature. As the effective substances are prepared at low temperature, the low molecular components which are easy to affect by temperature in the medicinal materials are not damaged and can be effectively extracted. The substances have outstanding contribution to treatment of diabetes. The low molecular substances can promote metabolism and immunity, so that the preparation is an innovative product of a traditional Chinese medicine preparation and has a positive effect for improving treatment of diabetes.

The invention provides compositions comprising Eno1 for delivery to a muscle. Further, the invention provides a method for normalizing blood glucose in a subject with elevated blood glucose, comprising administering to the subject enolase 1 (Eno1), thereby normalizing blood glucose in the subject. The invention also provides methods of treating one or more conditions including impaired glucose tolerance, insulin resistance, pre-diabetes, and diabetes, especially type 2 diabetes in a subject, comprising administering to the subject enolase 1 (Eno1), thereby treating the condition in the subject. In certain methods of the invention, the Eno1 is delivered to muscle.